

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080427 A1

(51) International Patent Classification⁷: C07K 14/72, A61K 39/00

(21) International Application Number: PCT/GB2005/000188

(22) International Filing Date: 18 January 2005 (18.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0403509.3 17 February 2004 (17.02.2004) GB

(71) Applicant (for all designated States except US): NEURO-TARGETS LIMITED [GB/GB]; Surrey Technology Centre, Oceam Road, Surry Research Park, Guildford GU2 5YG (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WYNICK, David; Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY (GB).

(74) Agents: DEAN, John, Paul et al.; Withers & Rogers LLP, Goldings House, 2 Hays Lane, London SE1 2HW (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/080427 A1

(54) Title: GALANIN RECEPTORS AND BRAIN INJURY

(57) Abstract: There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; chemical damage as the result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment; radiation damage; or immunological damage as the result of bacterial or viral infection. The brain disease may be one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.

Galanin Receptors and Brain Injury

TECHNICAL FIELD

5

This invention relates to the field of protecting the central nervous system from injury, damage or disease.

The invention relates especially, but not exclusively, to protecting or treating the brain 10 from the deleterious effects of (a) embolic, thrombotic or haemorrhagic stroke; (b) direct or indirect trauma to the brain or spinal cord; (c) surgery to the brain or spinal cord; (d) ischaemic or embolic damage to the brain resulting from cardiopulmonary bypass surgery, renal dialysis and reperfusion brain damage following myocardial infarction; (e) diseases 15 of the brain that involve neuronal damage and/or cell death, such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, vCJD (variant Creutzfeld Jacob Disease); (f) immunological, chemical or radiation damage to the brain such as that caused by bacterial or viral infections, alcohol, chemotherapy for tumours and radiotherapy for tumours.

In particular, the invention relates to the use of ligands of the second galanin receptor 20 subtype (GALR2), in the prevention or treatment of brain injury, damage or disease. Advantageously, a GALR2-specific agonist can be used to protect or treat a range of diseases of the central nervous system and would minimize or obviate potential side effects attributable to activation of GALR1 and/or GALR3. The invention also relates to drug discovery methods for determining candidate drugs for use in the prevention or treatment 25 of brain injury, damage or disease, and to pharmaceutical compositions for the prevention or treatment of brain injury, damage or disease.

BACKGROUND ART

30 **Stroke**

Stroke is defined as a cardiovascular accident, including an embolic, thrombotic or haemorrhagic episode that causes an area of brain anoxia, leading to permanent brain damage with associated functional neurological impairment. There are no satisfactory treatments for the neurological effects, despite stroke being the third-largest cause of death 35 in the Western world. Stroke is responsible for much of the physical disability observed in

the elderly population and up to 30% of stroke patients require long-term assistance with daily activities. The number of strokes occurring annually in the US has been estimated at over 700,000 and in the UK, at any one time, 500,000 people have had a stroke at some time in their life. A number of neuroprotective agents have been developed to attempt to

5 minimise the effects of a stroke but these have so far been disappointing in practice and are not in widespread or regular clinical use. These include, but are not limited to, the calcium channel antagonists nilvadipine (Nivadil[®]) from Fujisawa and nimodipine (Nimotop[®]) from Bayer; the antioxidants tirilazad (Freedox[®]) from Pharmacia & Upjohn and citicoline (CerAxon[®]) from Interneuron; and the protein kinase inhibitor fasudil (ErilTM) from Asahi.

10 In addition to calcium channel antagonists and free-radical scavengers, neuroprotective agents in development include N-methyl-D-aspartate (NMDA) antagonists, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonists and other compounds designed to inhibit release of toxic neurotransmitters such as glutamate and glycine agonists.

15

Forms of traumatic or surgical brain injury

A range of conditions exist, other than stroke, in which brain damage occurs. These include direct or indirect trauma or surgery to the brain or spinal cord, surgery involving cardiopulmonary bypass, renal dialysis and reperfusion following myocardial infarction.

20 The most common of these occurs during or after coronary artery bypass graft (CABG). 600,000 CABG surgeries are performed each year in the USA and 25% of all cardiopulmonary bypass patients exhibit neurological deficits within 3 months after surgery.

25 **Diseases that damage the brain**

Alzheimer's disease (AD) is a huge health burden in the Western world. AD is the commonest form of dementia in the elderly and there are currently an estimated 20 million people worldwide who have the disease. The incidence of AD is expected to double over the next 25 years as the population of elderly people increases. The annual cost of caring

30 for AD sufferers in the UK is in excess of £5.5 billion. To date, no known cure exists for the disease and few treatments (other than the acetylcoline esterase inhibitors) have been shown to substantially slow the progression of the disease.

Multiple Sclerosis (MS) is the most common disabling neurological disease among young adults and affects around 85,000 people in the UK and over half a million people in the Western World at any one time. MS is most often diagnosed in people between the ages of 20 and 40, and women are almost twice as likely to develop it as men. The disease seems 5 to preferentially target people of Northern European descent. MS is an autoimmune disease characterized by loss of the myelin sheath surrounding neurons resulting in progressive neuronal dysfunction and neuronal cell loss. Patients experience a range of problems that may include visual disturbance and blindness, loss of motor and/or sensory function and problems with bowel and urinary function.

10

Other diseases known to cause neuronal damage and/or cell death include Parkinson's Disease and variant Creutzfeld Jacob Disease.

Other forms of brain injury include immunological, chemical or radiation damage such as 15 that caused by bacterial or viral infections, alcohol, chemotherapy for tumours and radiotherapy for tumours.

Galanin

The twenty-nine amino-acid neuropeptide galanin (Tatemoto *et al.* (1983) FEBS Lett. **164** 20 124-128) is widely expressed in both the central and peripheral nervous system and has strong inhibitory actions on synaptic transmission by reducing the release of a number of classical neurotransmitters (Fisone *et al.* (1987) Proc. Natl. Acad. Sci. USA **84** 7339-7343; Misane *et al.* (1998) Eur. J. Neurosci. **10** 1230-1240; Pieribone *et al.* (1995) Neurosci. **64** 861-876; Hokfelt *et al.* (1998) Ann. N.Y. Acad. Sci. **863** 252-263; Kinney *et al.* (1998) J. 25 Neurosci. **18** 3489-3500; Zini *et al.* (1993) Eur. J. Pharmacol. **245** 1-7). These inhibitory actions result in a diverse range of physiological effects, including:

- a) an impairment of working memory (Mastropaoalo *et al.* (1988) Proc. Natl. Acad. Sci. USA **85** 9841-9845) and long term potentiation (LTP, thought to be the electrophysiological correlate of memory) (Sakurai *et al.* (1996) Neurosci. Lett. **212** 21-30 24);
- b) a reduction in hippocampal excitability with a decreased predisposition to seizure activity (Mazarati *et al.* (1992) Brain Res. **589** 164-166); and

c) a marked inhibition of nociceptive responses in the intact animal and after nerve injury (Wiesenfeld *et al.* (1992) Proc. Natl. Acad. Sci. USA **89** 3334-3337).

These neuromodulatory actions of galanin have long been regarded as the principal role
5 played by the peptide in the nervous system. However, there is now a large body of
evidence to indicate that injury to many of these neuronal systems markedly induces the
expression of galanin at both the mRNA and peptide levels. Examples of such lesion
studies include the up-regulation of galanin in:

a) the dorsal root ganglion (DRG) following peripheral nerve axotomy (Hokfelt *et al.*
10 (1987) Neurosci. Lett. **83** 217-220),
b) magnocellular secretory neurons of the hypothalamus after hypophysectomy (Villar *et
al.* (1990) Neurosci. **36** 181-199),
c) the dorsal raphe and thalamus after removal of the frontoparietal cortex (decortication)
(Cortes *et al.* (1990) Proc. Natl. Acad. Sci. USA **87** 7742-7746),
15 d) the molecular layer of the hippocampus after an entorhinal cortex lesion (Harrison &
Henderson (1999) Neurosci. Lett. **266** 41-44), and
e) the medial septum (MS) and vertical limb diagonal-band (vdB) after a fimbria fornix
bundle transection (Brecht *et al.* (1997) Brain Res. Mol. Brain Res. **48** 7-16).

These studies have led a number of investigators to speculate that galanin might play a cell
20 survival or growth promoting role in addition to its classical neuromodulatory effects.

To test this hypothesis, transgenic animals were generated, bearing loss- or gain-of-
function mutations in the galanin gene (Bacon *et al.* (2002) Neuroreport **13** 2129-2132;
Holmes *et al.* (2000) Proc. Natl. Acad. Sci. USA **97** 11563-11568; Steiner *et al.* (2001)
25 Proc. Natl. Acad. Sci. USA **98** 4184-4189; Blakeman *et al.* (2001) Neuroreport **12** 423-
425). Phenotypic analysis of galanin knockout animals demonstrated that, surprisingly, the
peptide acts as a survival factor to subsets of neurons in the developing peripheral and
central nervous system (Holmes, 2000; O'Meara *et al.* (2000) Proc. Natl. Acad. Sci. USA
97 11569-11574). Most recently, it has been demonstrated that this neuronal survival role
30 is also relevant to the adult DRG. Sensory neurons are dependent upon galanin for neurite
extension after injury, mediated by activation of the second galanin receptor subtype in a
PKC-dependent manner (Mahoney *et al.* (2003) J. Neurosci. **23** 416-421). It was therefore

hypothesised that galanin might also act in a similar manner in the central nervous system, reducing cell death in animal models of brain injury, damage or disease.

WO92/12997 discloses the sequence of human galanin. There is a discussion of studies by 5 other workers involving the administration of rat galanin or its N-terminal fragments to augment the effect of morphine. This patent application suggests that galanin can be expected to exhibit analgesic effects such that it may be administered alone or in combination with other analgesics. The application claims the use of galanin or its analogues in the treatment of pain and the use of galanin antagonists in the treatment of 10 certain other conditions.

WO92/20709 discloses a number of putative galanin antagonists. The antagonists which are described are all based on the first 12 amino acids of galanin followed by partial sequences of other peptides i.e. chimeric peptides. Some may be agonists, some 15 antagonists and some may be both depending on the receptor subtype. The application discloses that the antagonists may be useful for treatment of insulin-, growth hormone-, acetyl choline-, dopamine-, Substance P-, Somatostatin-, and noradrenaline-related conditions including Alzheimer's type dementia and intestinal disease, along with conditions in the fields of endocrinology, food intake, neurology and psychiatry. Such 20 antagonists may also be useful as analgesics. The application discloses the results of studies using some of the antagonists described therein on various effects such as galanin inhibition of glucose stimulated insulin release; galanin induced inhibition of scopolamine induced acetylcholine (ACh) hippocampal release; galanin induced facilitation of the flexor reflex; the displacement of bound iodinated galanin in membrane binding studies. 25 There is a suggestion in the application that the antagonists may be indicated for analgesia but there is no disclosure in the application of results to this effect. No positive or beneficial claims are made concerning the use of galanin agonists.

Ukai *et al.* (1995) Peptides 16 1283-1286 describes an investigation into the effects of 30 galanin on memory processes in mice. The results suggest that galanin impairs memory and other cognitive functions and that intermediate doses of galanin specifically elicit amnesia. No positive or beneficial claims are made concerning the use of galanin agonists.

JP-A-6172387 discloses a synthetic peptide and derivatives for effectively inhibiting the insulin-secretion suppressing action of galanin, expected to be useful as a galanin-antagonistic substance for the prevention and treatment of Alzheimer's Disease.

5 Bartfai *et al.* (1992) TiPS **13** 312-317 is a review article summarising the knowledge of the actions of galanin at that time and describing a series of high-affinity galanin antagonists. The review indicates that galanin antagonists may be useful in the treatment of Alzheimer's Disease.

10 Wynick *et al.* (1993) Nature **364** 529-532 discusses the involvement of galanin in basal and oestrogen-stimulated lactotroph function and the release of the hormone prolactin.

15 WO92/15681 discloses a peptide having the amino acid sequence of human galanin and DNA clones encoding the peptide. The application suggests that galanin may play a role in pancreatic activity and claims methods of modulating pancreatic activity, or of stimulating the production of growth hormone, the methods involving the use of the disclosed peptides.

20 WO92/15015 discloses DNA encoding human galanin and methods for the identification of galanin antagonists.

25 WO97/26853, US2003/0129702, US2003/0215823 and US6,586,191 disclose the isolation of the GALR2 (second galanin receptor subtype) cDNA encoding GALR2 and methods of identifying a chemical compound which specifically binds to GALR2. There is mention that GALR2 antagonists may be effective in the treatment of Alzheimer's Disease. There is no disclosure of methods of selecting a brain injury prevention or treatment compound, on the basis of whether or not a compound is a GALR2 agonist.

30 Crawley (1996) Life Sci. **58** 2185-2199 is a review article summarising the knowledge of the actions of galanin at that time. It indicates that centrally administered galanin produces deficits in learning and memory tasks in rats and that the use of galanin antagonists may be useful in the treatment of Alzheimer's Disease. No mention was made of the use of a galanin agonist for treatment of Alzheimer's Disease.

Liu et al. (1994) *J. Neurotrauma* **11** 73-82 describes the effect of intraventricular injection of galanin on the extent of traumatic brain injury (TBI) caused by central fluid percussion in rats and showed that galanin-treated rats had significantly less deficits in various sensory motor tasks. The paper attributes these effects to the neuromodulatory action of galanin, 5 decreasing the release of excitatory amino acids such as glutamate. However, there was no difference in a memory test (Morris water maze test) between galanin-treated and -untreated rats.

Luo et al. (1995) *Neuropeptide* **28** 161-166 is a study to examine the effects of acute 10 section of the sciatic nerve on the excitability of the flexor reflex in decerebrate, spinalised, unanaesthetised rats, as a measure of the development of chronic pain states. It was found that galanin may be useful in inhibiting the pain response. There is no mention of the use of GALR2 agonists to prevent or treat brain damage, injury or disease.

15 EP-A-0918455 discloses that recovery from crush injury (indicative of the regenerative abilities of sensory axons in the sciatic nerve), neuron survival during development and long term potentiation (LTP) are reduced in mice lacking the galanin gene compared to wild-type mice. From these results, it was proposed that galanin agonists may be suitable for use in the preparation of medicaments for the repair of nerve damage. There is also 20 mention that a galanin agonist is useful in the treatment of Alzheimer's Disease and associated memory loss. No mention was made of which galanin receptor subtype mediates these effects, nor the effects of galanin agonists in protecting the central nervous system from injury, damage or diseases other than Alzheimer's Disease.

25 In addition, the above patent application, along with EP-A-1342410, describes a mammal, particularly a mouse, which has been engineered such that it lacks the galanin gene.

30 WO02/096934 discloses a series of galanin agonist compounds which may be used to treat convulsive seizures such as those which take place in epilepsy. There is mention that such compounds could be used for CNS injuries or in open heart surgery to prevent anoxic damage. However, there is no support for this, since all experimental results included in WO02/096934 relate to the treatment of convulsive seizures. The research group of which the inventors for that application were a part subsequently published information relating

to one of these compounds, named “galnon” (Wu *et al.* (2003) *Eur. J. Pharmacol.* **482** 133-137). Galnon equally activates and has agonistic activity to both GALR1 and GALR2. In addition, recent work shows that this compound also activates a number of other GPCR receptors including the neuropeptides receptor (abstract Wang *et al.*, Functional activity of galanin peptide analogues. Program No. 960.4 2004 *Abstract Viewer/Itinerary Planner*. Washington DC: Society for Neuroscience, 2004. Online. (<http://sfn.scholarone.com/itin2004/index.html>)). Thus galnon is not specific in its activation of galanin receptors nor is it a GALR2-specific agonist. The patent application WO02/096934 claims use of galnon in the treatment of pain, epilepsy, but makes no specific claim in relation to the use of such a compound in the treatment of brain injury, trauma or disease.

10 Saar *et al.* (2002) *Proc. Natl. Acad. Sci. U.S.A.* **99** 7136-7141, Zachariou *et al.* (2003) *Proc. Natl. Acad. Sci. U.S.A.* **100** 9028-9033 and Abramov *et al.* (2003) *Neuropeptides* **38** 15 55-61 discuss the use of galnon in studies of epilepsy, opioid addiction and feeding, respectively.

Galant receptors

Three G-protein coupled galanin receptor subtypes have been identified, GALR1, GALR2 and GALR3 (Habert-Orton *et al.* (1994) *Proc. Natl. Acad. Sci. USA* **91** 9780-9783; Burgevin *et al.* (1995) *J. Mol. Neurosci.* **6** 33-41; Howard *et al.* (1997) *FEBS Letts.* **405** 285-290; Smith *et al.* (1997) *J. Biol. Chem.* **272** 24612-24616; Wang *et al.* (1997a) *Mol. Pharmacol.* **52** 337-343; Wang *et al.* (1997b) *J. Biol. Chem.* **272** 31949-31953; Ahmad *et al.* (1998) *Ann. N.Y. Acad. Sci.* **863** 108-119; Bloomquist *et al.* (1998) *Biophys. Res. Commun.* **243** 474-479; Kolakowski *et al.* (1998) *J. Neurochem.* **71** 2239-2251; Smith *et al.* (1998) *J. Biol. Chem.* **273** 23321-23326). Binding of galanin to GALR1 and GALR3 has been shown to inhibit adenylyl cyclase (Wang, 1998; Habert-Orton, 1994; Smith, 1998) by coupling to the inhibitory G_i protein. In contrast, activation of GALR2 stimulates phospholipase C and protein kinase C activity by coupling to G_{q/11} (Fathi, 1997; Howard, 1997; Wang, 1997a; Wittau *et al.* (2000) *Oncogene* **19** 4199-4209), hence activating the extracellular signal-regulated kinases (ERK) cascade. The negative coupling of GALR1 and GALR3 to adenylyl cyclase would be expected to have inhibitory effects on neuronal function after nerve injury or disease. In turn, this would be predicted to have negative and

unwanted effects on behaviour and inhibit or delay recovery after injury and disease. Further, GALR1 and GALR3 are both expressed in the heart and gut, GALR1 also being expressed in the lung and bladder.

5 The lack of receptor subtype-specific antisera and the paucity of galanin ligands that are receptor subtype-specific, continues to hamper the analysis of the functional roles played by each receptor. A major advance in the field has been the discovery that galanin 2-11 peptide (termed AR-M1896) preferentially binds to GALR2 with a 500-fold specificity compared to GALR1 and with an almost complete loss of GALR1 activation (Liu *et al.*
10 (2001) Proc. Natl. Acad. Sci. USA **98** 9960-9964; Berger *et al.* (2004) Endocrinology **145** 500-507). There is no published data as to whether AR-M1896 binds, or activates, GALR3. AR-M1896 has previously been used to demonstrate that activation of GALR2 appears to be the principal mechanism by which galanin stimulates neurite outgrowth from adult
15 sensory neurons of the peripheral nervous system (Mahoney, 2003). Galanin 1-15 peptide and galanin 1-16 peptide are also known to be portions of the full-length galanin neuropeptide which will activate a galanin receptor.

Throughout this specification, the term “GALR” indicates a receptor which is one of the group of receptors consisting of GALR1, GALR2 and GALR3. The group includes,
20 without limitation, the human, rat and mouse receptors. The receptor may also be chimaeric in form (i.e. including GALR sequences from different species), truncated (i.e. shorter than a native GALR sequence) or extended (i.e. including additional sequence beyond that of a native GALR sequence). Activation of the receptor may be determined, for example, by an increase in intracellular calcium levels.

25

Throughout this specification, the term “GALR2-specific agonist” indicates a substance capable of triggering a response in a cell as a result of the activation of GALR2 by the substance, but which does not activate (or activates with less potency) GALR1 and/or GALR3. Methods of identifying whether or not a compound is an agonist of a galanin receptor are known in the art, for example, Botella *et al.* (1995) Gastroenterology **108** 3-11 and Barblivien *et al.* (1995) Neuroreport **6** 1849-1852. A GALR2-specific agonist is one that preferentially binds and activates GALR2 with a selectivity of at least 30-fold compared to binding and activation of GALR1, preferably with greater than 50-fold

selectivity over GALR1 and more preferably with greater than 100-fold selectivity over GALR1. The GALR2-specific agonist may also preferentially bind and activate GALR2 with a selectivity of at least 30-fold compared to binding and activation of GALR3, preferably with greater than 50-fold selectivity over GALR3 and more preferably with 5 greater than 100-fold selectivity over GALR3.

DISCLOSURE OF INVENTION

According to a first aspect of the invention, there is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain 10 damage, injury or disease.

Advantageously, the use of a GALR2-specific agonist allows the prevention of brain damage, injury or disease, or an improvement in the condition of individuals who have 15 suffered such brain damage, injury or disease, as a result of the ability of galanin and galanin agonists to reduce cell death in such situations. Galanin also acts as an endogenous neuroprotective factor to the hippocampus. A GALR2-specific agonist which does not activate GALR1 and/or GALR3 has benefits in treating brain injury or disease, minimizing unwanted or harmful peripheral side effects attributable to activation of GALR1 or 20 GALR3, as the result of the different signaling cascades utilized by each of the three receptors.

The brain injury or damage may be caused by one of: embolic, thrombotic or 25 haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage. The immunological damage may be the result of bacterial or viral infection. The chemical damage may be the result of excess alcohol consumption or administration of chemotherapy agents for cancer 30 treatment. The radiation damage may be the result of radiotherapy for cancer treatment.

The brain disease is preferably one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.

The GALR2-specific agonist may be a polypeptide comprising a portion of the galanin amino acid sequence and preferably is AR-M1896.

5 Alternatively, the GALR2-specific agonist may be a non-peptide small chemical entity.

The GALR2-specific agonist may have a binding affinity for GALR2 of between 0 and 100 μ M, preferably between 0 and 1 μ M and has a greater than 30-fold binding specificity for GALR2 over GALR1, preferably greater than 50-fold binding specificity, most 10 preferably greater than 100-fold binding specificity. The GALR2-specific agonist may also have greater than 30-fold binding specificity for GALR2 over GALR3, preferably greater than 50-fold binding specificity, most preferably greater than 100-fold binding specificity.

15 According to a second aspect of the invention, there is provided a method for preventing or treating brain injury, damage or disease comprising administering an effective amount of a GALR2-specific agonist to an individual in need of such prevention or treatment. Preferably, the individual is a human individual.

20 The brain injury or damage may be caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage. The immunological damage may be the result of bacterial or viral infection. The chemical damage may be the 25 result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment. The radiation damage may be the result of radiotherapy for cancer treatment.

30 The brain disease is preferably one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.

The GALR2-specific agonist may be a polypeptide comprising a portion of the galanin amino acid sequence and preferably is AR-M1896.

Alternatively, the GALR2-specific agonist may be a non-peptide small chemical entity.

The GALR2-specific agonist may have a binding affinity for GALR2 of between 0 and 100 μ M, preferably between 0 and 1 μ M and has a greater than 30-fold binding specificity for GALR2 over GALR1, preferably greater than 50-fold binding specificity, most preferably greater than 100-fold binding specificity. The GALR2-specific agonist may also have greater than 30-fold binding specificity for GALR2 over GALR3, preferably greater than 50-fold binding specificity, most preferably greater than 100-fold binding specificity.

According to a third aspect of the invention, there is provided a method of selecting a candidate brain injury, damage or repair prevention or treatment compound, comprising determining whether at least one test compound is a GALR2-specific agonist and selecting the at least one test compound as a candidate compound if it is a GALR2-specific agonist.

It may be determined that the at least one test compound binds to GALR2 with a binding affinity of between 0 and 100 μ M, preferably between 0 and 1 μ M. The test compound is greater than 30-fold selective, preferably greater than 50-fold selective and most preferably greater than 100-fold selective for binding to GALR2 compared to binding to GALR1. Preferably, the test compound is also greater than 30-fold selective, preferably greater than 50-fold selective and most preferably greater than 100-fold selective for binding to GALR2 compared to binding to GALR3.

The GALR2 may comprise at least a portion of human GALR2, or may be full-length human GALR2.

The GALR2 may comprise at least a portion of non-human GALR2, preferably rat or mouse GALR2, or may be full-length GALR2.

The GALR2 may be a chimeric receptor construct.

Using a method according to this aspect of the invention, a selection of test compounds may be screened in a high throughput screening assay.

According to a fourth aspect of the invention, there is provided a pharmaceutical composition for use in the prevention or treatment of brain injury, damage or disease, the composition comprising:

- 5 a) an effective amount of at least one GALR2-specific agonist, or pharmaceutically acceptable salts thereof; and
- b) a pharmaceutically suitable adjuvant, carrier or vehicle.

The brain injury or damage may be caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; 10 ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage. The immunological damage may be the result of bacterial or viral infection. The chemical damage may be the result of excess alcohol consumption or administration of chemotherapy agents for cancer 15 treatment. The radiation damage may be the result of radiotherapy for cancer treatment.

The brain disease is preferably one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.

20 The GALR2 specific-agonist may be a polypeptide comprising a portion of the galanin amino acid sequence and preferably is AR-M1896.

Alternatively the GALR2 specific-agonist may be a non-peptide small chemical entity.

25 The GALR2 specific-agonist may have a binding affinity for GALR2 of between 0 and 100 μ M, preferably between 0 and 1 μ M and has a greater than 30-fold binding specificity for GALR2 over GALR1, preferably greater than 50-fold binding specificity, most preferably greater than 100-fold binding specificity. The GALR2-specific agonist may also have greater than 30-fold binding specificity for GALR2 over GALR3, preferably greater than 50-fold binding specificity, most preferably greater than 100-fold binding specificity.

The pharmaceutically suitable adjuvant, carrier or vehicle may be selected from: ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, 5 such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

10

The pharmaceutical composition may be administered orally or parenterally, preferably orally.

Where the pharmaceutical composition is administered orally, it may be in the form of 15 a capsule or a tablet, and may preferably comprise lactose and/or corn starch. The pharmaceutical composition may further comprise a lubricating agent, preferably magnesium stearate. The pharmaceutical composition may be in the form of an aqueous suspension or aqueous solution, and may further comprise an emulsifying agent and/or a suspending agent. The pharmaceutical composition may comprise sweetening, flavouring 20 and/or colouring agents.

The pharmaceutical composition may alternatively be administered by injection, by use of a needle-free device, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

25

Where the pharmaceutical composition is administered by injection or needle-free device, it may be in the form of a sterile injectable preparation or a form suitable for administration by needle-free device. The sterile injectable preparation or form suitable for administration by needle-free device may be an aqueous or an oleaginous suspension, or a 30 suspension in a non-toxic parenterally-acceptable diluent or solvent. The aqueous suspension may be prepared in mannitol, water, Ringer's solution or isotonic sodium chloride solution. The oleaginous suspension may be prepared in a synthetic monoglyceride, a synthetic diglyceride, a fatty acid or a natural pharmaceutically-

acceptable oil. The fatty acid may be an oleic acid or an oleic acid glyceride derivative. The natural pharmaceutically-acceptable oil may be an olive oil, a castor oil, or a polyoxyethylated olive oil or castor oil. The oleaginous suspension may contain a long-chain alcohol diluent or dispersant, preferably Ph. Helv.

5

Where the pharmaceutical composition is administered rectally, it may be in the form of a suppository for rectal administration. The suppository may comprise a non-irritating excipient which is solid at room temperature and liquid at rectal temperature. The non-irritating excipient may be one of cocoa butter, beeswax or a polyethylene glycol.

10

Where the pharmaceutical composition is administered topically, it may be an ointment comprising a carrier selected from mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene-polyoxypropylene compounds, emulsifying wax and water. Alternatively, it may be a lotion or cream comprising a carrier selected from mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

15

Where the pharmaceutical composition is administered nasally, it may be administered by nasal aerosol and/or inhalation.

20

According to a fifth aspect of the invention, there is provided a method of inhibiting the death of a cell comprising contacting the cell with an amount of a GALR2-specific agonist effective to inhibit the death of the cell. The cell may a neuron, preferably a neuron from the central nervous system, preferably a hippocampal or cortical neuron. Preferably, the cell is a human cell. In this method, the death of a cell is inhibited as the result of the activation of GALR2 present in the cell. The death of a cell is inhibited if the probability of the occurrence of the cell's death is decreased and/or if the life of the cell is prolonged.

25

BRIEF DESCRIPTION OF DRAWINGS

30

Embodiments of the invention will now be described, by way of example only, with reference to the accompanying Figures 1-4, in which:

Figure 1 shows the effects of intraperitoneal administration of 20mg/Kg kainate on hippocampal cell death *in vivo*;

5 Figure 2 shows the responses of galanin knockout, over-expressing and wild-type hippocampal cultures *in vitro* after incubation with 10nM - 1μM staurosporine (St);

Figure 3 shows the effect of co-administration of staurosporine or glutamate with galanin or AR-M1896 on galanin wild-type hippocampal cultures *in vitro*; and

10 Figure 4 shows the responses of galanin knockout, over-expressing and wild-type animals in the Experimental Autoimmune Encephalomyelitis (EAE) model of MS *in vivo*.

MODES OF CARRYING OUT THE INVENTION

15 Methods

Animals

All animals were fed standard chow and water *ad libitum*. Animal care and procedures were performed within the United Kingdom Home Office protocols and guidelines.

20

Galanin knockout mice

Details of the strain and breeding history have been published previously (Wynick *et al.* (1998) Proc. Natl. Acad. Sci. USA **95** 12671-12676). In brief, mice homozygous for a targeted mutation in the galanin gene were generated using the E14 cell line. A PGK-Neo cassette in reverse orientation was used to replace exons 1-5, and the mutation was bred to homozygosity and has remained inbred on the 129OlaHsd strain. Age and sex matched wild-type littermates were used as controls in all experiments.

25

Galanin over-expressing mice

Details of the strain and breeding history have been published previously (Bacon *et al.* (2002) Neuroreport 13 2129-2132) In brief, galanin over-expressing mice were generated on the CBA/B6 F1 hybrid background. A mouse 129sv cosmid genomic library was screened and a ~25kb region was subcloned which contained the entire murine galanin

coding region and ~20kb of upstream sequence. The transgene was excised by restriction digest and microinjected into fertilised oocytes at 5ng/µl final concentration. Four galanin over-expressing transgenic lines were generated as previously described (Bacon *et al.* (2002) *Neuroreport* 13 2129-2132) and galanin expression in the hippocampus was assessed by immunocytochemistry (see below). Line 46 was found to have highest levels of galanin expression in the CA1 and CA3 regions of the hippocampus and in the dentate gyrus compared to the three other lines and wild-type controls. Line 46 was therefore used for all subsequent experiments.

10 *Organotypic hippocampal cultures*

Organotypic cultures were prepared as previously described (Elliott-Hunt *et al.* (2002) *J. Neurochem.* **80** 416-425; Stoppini *et al.* (1991) *J. Neurosci. Methods* **37** 173-182). Briefly, the hippocampi from 5-6 day old pups were rapidly removed under a dissection microscope and sectioned transversely at 400µm using a McIlwain tissue chopper (Mickle Laboratory Engineering Co. Ltd., Gomshall, UK). The slices were cultured in 95% air and 5% CO₂ at 37°C on a microporous transmembrane biopore membrane (Millipore, Poole, UK), in a 6-well plate, in 50% minimal essential medium with Earle's Salts (Gibco BRL, Paisley, UK) without L-glutamine, 50% Hanks Balanced Salt Solution (Gibco BRL), 25% Horse Serum (heat inactivated; Harlan Serum Labs, Loughborough, UK), 5mg/ml glucose (Sigma Chemical Co., Poole, UK) and 1ml glutamine (Sigma).

20 *Preparation of primary neuronal cultures*

Hippocampi from 2-3 day old pups were dissected and placed into 4°C collection buffer prepared with Hanks Balanced Salt Solution (calcium and magnesium free) (Gibco BRL, Paisley, UK), 10% (v/v) N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (ICN Biomedicals Inc., Aurora, Ohio, USA), 50U/ml penicillin (Britannia Pharmaceuticals Ltd., Redhill, Surrey, UK), 0.05mg/ml streptomycin in 100ml (Sigma Chemical Company, Poole, Dorset, UK), and 0.5% (v/v) Bovine Serum Albumin (BSA; ICN Biomedicals Inc., Aurora, Ohio, USA). Enzymatic digestion, isolation and culture of hippocampal neurons was performed as previously described (McManus & Brewer (1997) *Neurosci. Lett.* **224** 193-196). Cells were counted and plated at 40,000 cells/well onto D-L-poly-ornithine (Sigma) coated 96 well plates. After 24 hours 10 µg/ml 5'Fluoro 2' Deoxyuridine (Sigma; anti-mitotic agent) was added. Cultures were incubated at 37°C with ambient oxygen and

5% CO₂ for 9 days before experimentation. The media was changed after the first 3 days and then every fourth day thereafter.

Immunohistochemistry

5 Mice were intracardially perfused with 4% paraformaldehyde/Phosphate Buffered Saline (PBS). The brains were removed and post-fixed for 4 hours at room temperature. The brains were then equilibrated in 20% sucrose overnight at 4°C, embedded in Optimal Cutting Temperature (OCT) compound (Tissue Tek Ltd., Eastbourne, UK) mounting medium, frozen on dry ice, and cryostat-sectioned (30µm sections). Sections were blocked 10 and permeabilised in 10% normal goat serum/PBS 0.2% Triton X-100 (PBST) for 1 hour at room temperature. Sections were then incubated in rabbit polyclonal antibody to galanin (Affinity, Nottingham, UK) at 1:1000 in PBST overnight at room temperature, washed 3 x 10 minutes in PBS, and incubated in fluorescein isothiocyanate (FITC)-goat (The Jackson Laboratory, Westgrove, PA, USA) at 1:800 for 3 hours at room temperature. After 15 washing, sections were mounted in Vectashield™ (Vector Laboratories Inc., Burlington, CA, USA). Images were taken by using a Leica fluorescent microscope (Leica Microsystems, Milton Keynes, UK) with RT Color Spot camera and Spot Advance image capture system software (Diagnostic Instruments, Sterling Heights, MI, USA).

20 Galanin immunohistochemistry was also performed on dispersed hippocampal neurons and organotypic cultures which were fixed in 4% paraformaldehyde, permeabilised with Triton X-100 and then processed as above.

Staurosporine and glutamate induced hippocampal damage

25 Fourteen day organotypic hippocampal cultures were placed in 0.1% BSA with serum free media for 16 hours before incubation with varying concentrations of glutamic acid for 3 hours or staurosporine for 9 hours. Staurosporine and glutamate are both known to cause excitotoxic damage to such cell cultures (Prehn *et al.* (1997) J. Neurochem. **68** 1679-1685; Ohmori *et al.* (1996) Brain Res. **743** 109-115). Cultures were washed with serum-free 30 medium and incubated for a further 24 hours before imaging. Regional patterns of neuronal injury in the organotypic cultures were observed by performing experiments in the presence of propidium iodide. After membrane injury, the dye enters cells, binds to nucleic acids and accumulates, rendering the cell brightly fluorescent (Vornov *et al.* (1994) Stroke

25 457-465). The CA1 neuronal subfield was clearly visible in a bright field image. Neuronal damage in the area encompassing the CA1 region was assessed using the density slice function in NIH Image software (Scion Image, MD, USA) to establish signal above background. The area of the subfields expressing the exclusion dye propidium iodide was
5 measured, and expressed as a percentage of the total area of the subfields as assessed in the bright field image. Furthermore, for consistency in setting the parameters accurately when using the density slice function, the threshold was set against a positive control set of cultures exposed to 10mM glutamate.

10 Nine-day primary hippocampal cultures were exposed to staurosporine for 24 hours. The viability of neurons was measured by manual counting of both live and dead neurons using a live/dead kit (Molecular Probes, Lieden, Netherlands).

Treatments

15 Organotypic or dispersed primary hippocampal cultures were at various times cultured with or without the addition of the following chemicals: staurosporine (Sigma), L-glutamic acid (Sigma), galanin peptide (Bachem, Merseyside, UK), the high-affinity GALR2-specific agonist AR-M1896 [Gal(2-11)Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-NH₂] (AstraZeneca, Montreal, Quebec, Canada), amyloid- β (1-42) (A β (1-42)) and
20 the reverse A β (42-1) peptide (American Peptide Company, Sunnyvale, CA 93906). Before use in the experiments below, the A β (1-42) was induced to form fibrils by pre-incubation in culture medium. Specifically, 0.45mg of A β peptide was dissolved in 20 μ l of dimethyl sulfoxide (DMSO -Sigma) and diluted to a 100- μ M stock solution in medium, which was then incubated with gentle shaking at room temperature for 24 hours.

25

Kainate-induced hippocampal injury

8-week old female mice were injected with intraperitoneal (i.p.) kainic acid (Tocris Cookson, Bristol, UK) (20mg/kg) or vehicle (PBS, 1ml/kg). Kainic acid is known to cause hippocampal damage as previously described (Beer *et al.* (1998) *Brain Res.* **794** 255-266; Mazarati *et al.* (2000) *J. Neurosci.* **16** 6276-6281). Hippocampal cell death was measured by terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL). Animals were killed at 72 hours after injection with kainic acid or vehicle. Mice were intracardially perfused with 4% paraformaldehyde/PBS and the brains rapidly

removed and post fixed for 4 hours at room temperature. The brains were equilibrated in 20% sucrose overnight at 4°C, embedded in OCT mounting media and frozen on dry ice. Sections were cut (16µm) on a cryostat, thaw mounted onto gelatine coated slides and stored at -80°C until use. Apoptosis was evaluated by using an *in situ* cell detection kit (Boehringer, BerksHire, UK). Every sixth section was collected and blocked with methanol and permeabilised with triton (0.1%) and sodium citrate (0.1%) and then labelled with fluorescein dUTP in a humid box for 1 hour at 37°C. The sections were then combined with horse radish peroxidase, colocalised with diaminobenzidine (DAB) and counterstained with haemytoxin. Controls received the same management except the labelling omission of fluorescein dUTP. After washing, sections were mounted in Vectashield™ (Vector Labs Inc.). Cells were visualised using a Leica fluorescent microscope with RT Colour Spot camera and Spot Advance image capture system software (Diagnostic Instruments Inc., Sterling Heights, MI, USA).

15 *EAE model*

The standard EAE model of MS was used as previously described (Radu *et al.* (2000) Int. Immunol. 12 1553–60). Mice were immunized subcutaneously in one hind leg with a total of 200 µg of MBP 1–9 (AcASQKRPSQR, synthesized by Abimed, Langenfeld, Germany), emulsified with complete Freund's adjuvant (Sigma) supplemented with 4 mg/ml *Mycobacterium tuberculosis* strain H37RA (Difco, Detroit, MI). *M. tuberculosis* purified protein derivative (PPD) was obtained from the UK Central Veterinary Laboratory (Weybridge, UK). Mice were scored for symptoms of EAE as follows: 0, no signs; 1, flaccid tail; 2, partial hind limb paralysis and/or impaired righting reflex; 3, full hind limb paralysis; 4, hind limb plus fore limb paralysis; and 5, moribund or dead.

25

Statistical analysis

Data are presented as the mean + SEM. Student's t test was used to analyse the difference in staurosporine concentrations within groups. ANOVAs or non-parametric Mann-Whitney U post hoc tests were used as appropriate to analyse differences between genotypes and different ligands and/or staurosporine and glutamate points. A P value of <0.05 was considered to be significant.

Candidate compound screening method

CHO cells transfected with and stably expressing the cDNA encoding either the human GALR1, GALR2 or GALR3 were obtained from Euroscreen (Brussels, Belgium). Cells were cultured in Nutrient Mix (HAMS) F12 (Gibco BRL, Paisley, UK), supplemented with 5 10% foetal bovine serum (Gibco BRL) and 0.4mg/ml G418 (Sigma) in 3 layer culture flasks at 37°C in a 5%CO₂/95% air atmosphere. Cells were grown to approximately 80% confluence and dissociated in 0.02% EDTA in D-PBS for 10 minutes at 37°C. Cells were collected by centrifugation at 1000rpm for 5 minutes and then resuspended in medium to the required density on the day of the experiment. Cellular responses to the addition of 10 various compounds were then measured using a FLIPR384 (Molecular Devices Ltd, Wokingham, UK). Cells were suspended in culture medium at a density of 20,000 cells/30µl, transferred to 384 well black/clear Greiner culture plates (30µl/well) and incubated at 37°C in a 5% CO₂/95% air humidified atmosphere for 2 hours. Cells were loaded with dye by the addition of 30µl Fluo-4-AM (4µM in assay buffer with 0.8% 15 pluronic F-127 and 1% FBS) to each well and incubated at 37°C in a 5% CO₂/95% air humidified atmosphere for 1 hour. Cells were washed in FLIPR assay buffer (HBSS without calcium or magnesium with the addition of 20mM Hepes, 1mM MgCl₂, 2mM CaCl₂, 2.5mM Probenecid and 0.1% BSA) using an EMLA plate washer (4 x 80µl washes) such that 45µl remained in each well after washing.

20 Responses to compounds were measured using a FLIPR384. Basal fluorescence was recorded for every second for 10 seconds prior to compound addition (5µl; final concentration 10µM) and fluorescence recorded every second for 60 readings then every 6 seconds for a further 20 readings. Data were recorded as relative fluorescence units (RFU) 25 and analysis was performed on exported statistics recording maximum RFU over the 3min recording. Data were analysed using XLFit 3.0. All data were subjected to the relevant quality control (QC) procedure prior to release. EC50 for each compound was calculated for each of the GALR expressing cell lines and from that data, compounds which acted as GALR2-specific-agonists were identified.

Results

Experiment 1

Intraperitoneal administration of 20mg/kg kainic acid was used to induce excitotoxic hippocampal damage as previously described (Beer, 1998; Mazarati, 2000; Tooyama *et al.* 5 (2002) *Epilepsia* **43 Suppl 9** 39-43). Three days later brains were harvested and hippocampal cell death assessed by counting the number of TUNEL-positive cells. The results are displayed in Figure 1. The number of apoptotic neurons was significantly greater in both the CA1 and CA3 regions of the galanin knockout animals (KO) compared 10 to the strain-matched wild-type controls (WT) (Figure 1), an increase of 62.9% and 44.8% respectively (**P<0.01, ***p<0.001). Conversely, the degree of cell death was significantly lower in both the CA1 and CA3 regions of the galanin over-expressing animals (OE) than in strain matched controls (WT) (Figure 1), a decrease of 55.6% and 15 50.4% respectively (p<0.05).

Experiment 2

To further dissect the neuroprotective role played by galanin in a more tractable *in vitro* system, both primary dispersed and organotypic hippocampal cultures (Elliott-Hunt, 2002) 20 were used. These two techniques are complimentary since the dispersed hippocampal cultures ensure that observed effects are neuron-specific, whilst the organotypic cultures preserve the synaptic and anatomical organisation of the neuronal circuitry (Elliott-Hunt, 2002) as well as retaining many of the functional characteristics found *in vivo* (Adamschik *et al.* (2000) *Brain Res. Prot.* **5** 153-158). The effects of staurosporine and glutamate on 25 neuronal cell death in hippocampal cultures (Prehn, 1997; Ohmori, 1996) were studied. Cell death was visualised by propidium iodide staining. Results are expressed as a percentage of the area expressing fluorescence as compared with the untreated "control" cultures. Staurosporine at 1 μ M and 100nM caused significant and consistent levels of neurotoxicity in both the wild-type (WT) and galanin knockout (KO) cultures. The 30 percentage cell death was significantly higher in galanin knockout animals compared to wild-type controls at both doses (1 μ M: 68 \pm 0.5% vs 38 \pm 8%; 100nM: 65 \pm 10% vs 40 \pm 26%; n=4, p<0.05), as shown in Figure 2A. Similarly, a marked and significant excess of cell death in the galanin knockout organotypic cultures after 9 hour exposure to 4mM

glutamate was noted, compared to wild-type controls ($85 \pm 8.6\%$ vs $61 \pm 9.3\%$; n=4, p<0.05).

5 To ensure that the above effects were neuron-specific, the effects of staurosporine in dispersed primary hippocampal neurons were also studied. Once again a significant excess of cell death in the galanin knockout cultures was observed, compared to wild-type controls (n=4, p<0.01), over the range of 10nM - 1 μ M staurosporine (Figure 2B).

Experiment 3

10 Having demonstrated that an absence of galanin increases the susceptibility to hippocampal cell death, the studies were extended to the galanin over-expressing mice. A significant reduction in cell death was observed in the galanin over-expressing animals (OE) after exposure to 50nM or 100nM staurosporine, compared to strain-matched wild-type controls (WT) (Figure 2C; n=4, **p<0.01, ***p<0.001).

15

Experiment 4

To test whether exogenous galanin would protect wild-type hippocampal neurons from damage, 100mM galanin was co-administered with 100nM staurosporine to wild-type organotypic cultures. This co-administration provided significant neuroprotection (n=4, p<0.05) in these cultures (Figure 3A). Similarly, galanin was also protective over the dose 20 range 10nM - 1 μ M when co-administered with 4mM glutamate in wild-type organotypic cultures (Figure 3B). In keeping with these findings using organotypic cultures, 100nM galanin also protected wild-type dispersed primary hippocampal neurons from cell death induced by 10nM staurosporine (Figure 3C; n=3, p<0.05).

25

Experiment 5

The neuroprotective effects of galanin in the hippocampus are likely to be mediated by activation of one or more of three G-protein coupled galanin receptor subtypes, GALR1, GALR2 and GALR3. It has previously been shown that activation of GALR2 appears to be 30 the principal mechanism by which galanin stimulates neurite outgrowth from adult sensory neurons (Mahoney, 2003). Therefore, the effect of 100nM AR-M1896 (a high-affinity GALR2-specific agonist), when co-administered with 100nM staurosporine in organotypic cultures from wildtype animals, was also tested. It should be noted that even if AR-M1896

does weakly activate GALR1, this would be most unlikely at 100nM when the IC₅₀ for GALR1 is 879nM. AR-M1896 significantly reduced the amount of cell death in wild-type organotypic cultures to a similar amount observed with equimolar concentrations of galanin (p<0.05, Figure 3A). The addition of AR-M1896 was also as effective in reducing 5 staurosporine-induced cell death in galanin knockout cultures as that observed in the wild-type organotypic cultures (data not shown). Dispersed primary hippocampal neurons were also treated with AR-M1896 and staurosporine, demonstrating similar protective effects of the peptide to that observed with full-length galanin (Figure 3C). No significant effects of galanin or AR-M1896 were noted in the absence of staurosporine in organotypic or 10 primary cultures.

Experiment 6

Disease progression in AD is associated with the deposition of amyloid- β fibrils in the brain to form senile plaques consisting of peptides derived from the cleavage of the 15 amyloid precursor protein by α -secretases (Gamblin *et al.* (2003) Proc. Natl. Acad. Sci. U.S.A. **100** 10032-10037). Deposits of fibrillar amyloid- β are assumed to have a causative role in the neuropathogenesis of AD. To test whether endogenous galanin lays a protective effects on neuronal toxicity induced by fibrillar A β , 14 day old hippocampal organotypic cultures were obtained from galanin knockout, galanin over-expressing and strain matched 20 wild-type controls transgenic animals. These cultures were treated for up to 72 hours with 10 μ M fibrillar A β (1-42), the reverse control peptide A β (42-1) or the addition of no peptide. 10 μ M fibrillar A β (1-42) was used as previously described (Zheng *et al.* (2002) Neuroscience **115** 201-211.). Experiments were performed in triplicate and cell death was 25 measured as above using propidium iodide fluorescence (PIF) intensity. Images were captured and analysed using Scion Image analysis software. The results demonstrate a statistically greater amount of fibrillar A β (1-42)-induced hippocampal cell death in the galanin knock-out animals compared to wild-type controls. Conversely, significantly less fibrillar A β (1-42)-induced hippocampal cell death was noted in the galanin over-expressing animals compared to strain-matched wild-type controls.

30

Experiment 7

MS phenotype was induced in galanin knock-out, galanin over-expressing and strain matched wild-type control transgenic animals, using the previously described EAE model

described above. Figure 4A demonstrates that the galanin knockout animals develop an accelerated and more severe form of the disease compared to strain matched wildtype controls (N=5, P<0.01). Conversely, the galanin over-expressing mice fail to develop any symptoms of the disease in marked contrast to their wildtype controls (Figure 4B; N=5, 5 P<0.001). These data demonstrate once again that galanin plays a protective role in an inflammatory model of neuronal injury in the central nervous system.

SUMMARY

It has been demonstrated that galanin acts as an endogenous neuroprotective factor to the hippocampus, in a number of *in vivo* and *in vitro* models of injury. Further, exogenous galanin and a previously described high-affinity GALR2-specific agonist both reduced cell death. Therefore, GALR2 is the principal receptor subtype that mediates these protective effects. These data indicate that a GALR2-specific agonist will have therapeutic uses in the treatment or prevention of various forms of brain injury, damage or disease.

Claims

1. The use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease.
- 5 2. The use according to claim 1 wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage.
- 10 3. The use according to claim 2 wherein the immunological damage is the result of bacterial or viral infection.
4. The use according to claim 2 wherein the chemical damage is the result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment.
5. The use according to claim 2 wherein the radiation damage is the result of 15 radiotherapy.
6. The use according to claim 1 or 2 wherein the brain disease is one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.
7. The use according to any preceding claim wherein the GALR2-specific agonist is a polypeptide comprising a portion of the galanin amino acid sequence.
- 20 8. The use according to claim 7 wherein the GALR2-specific agonist is AR-M1896.
9. The use according to any of claims 1-6 wherein the GALR2-specific agonist is a non-peptide small chemical entity.
10. The use according to any preceding claim wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 30-fold binding 25 specificity for GALR2 over GALR1.
11. The use according to any preceding claim wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 50-fold binding specificity for GALR2 over GALR1.
12. The use according to any preceding claim wherein the GALR2-specific agonist has a 30 binding affinity for GALR2 of between 0 and 100 μ M and greater than 100-fold binding specificity for GALR2 over GALR1.
13. The use according to any of claims 10-12 wherein the GALR2-specific agonist has a greater than 30-fold binding specificity for GALR2 over GALR3.

14. The use according to any of claims 10-12 wherein the GALR2-specific agonist has a greater than 50-fold binding specificity for GALR2 over GALR3.
15. The use according to any of claims 10-12 wherein the GALR2-specific agonist has a greater than 100-fold binding specificity for GALR2 over GALR3.
- 5 16. The use according to any of claims 10-15 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 1 μ M.
17. A method for preventing or treating brain injury, damage or disease comprising administering an effective amount of a GALR2-specific agonist to an individual in need of such prevention or treatment.
- 10 18. A method according to claim 17 wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage.
- 15 19. A method according to claim 18 wherein the immunological damage is the result of bacterial or viral infection.
20. A method according to claim 18 wherein the chemical damage is the result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment.
21. A method according to claim 18 wherein the radiation damage is the result of radiotherapy.
- 20 22. A method according to claim 17 or 18 wherein the brain disease is one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.
23. A method according to any of claims 17-22 wherein the GALR2-specific agonist is a polypeptide comprising a portion of the galanin amino acid sequence.
- 25 24. A method according to claim 23 wherein the GALR2-specific agonist is AR-M1896.
- 25 25. A method according to any of claims 17-22 wherein the GALR2-specific agonist is a non-peptide small chemical entity.
26. A method according to any of claims 17-25 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 30-fold binding specificity for GALR2 over GALR1.
- 30 27. A method according to any of claims 17-26 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 50-fold binding specificity for GALR2 over GALR1.

28. A method according to any of claims 17-27 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 100-fold binding specificity for GALR2 over GALR1.

29. A method according to any of claims 26-28 wherein the GALR2-specific agonist has greater than 30-fold binding specificity for GALR2 over GALR3.

5 30. A method according to any of claims 26-29 wherein the GALR2-specific agonist has greater than 50-fold binding specificity for GALR2 over GALR3.

31. A method according to any of claims 26-30 wherein the GALR2-specific agonist has greater than 100-fold binding specificity for GALR2 over GALR3.

10 32. A method according to any of claims 26-31 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 1 μ M.

33. A method of selecting a candidate brain injury, damage or repair prevention or treatment compound, comprising determining whether at least one test compound is a GALR2-specific agonist and selecting the at least one test compound as a candidate compound if it is a GALR2-specific agonist.

15 34. A method according to claim 33 wherein it is determined that the at least one test compound binds to GALR2 with a binding affinity of between 0 and 100 μ M and with a specificity of greater than 30-fold for GALR2 over GALR1.

35. A method according to claim 33 or 34 wherein it is determined that at least one test compound binds to GALR2 with a binding affinity between 0 and 100 μ M and with a specificity of greater than 50 fold for GALR2 over GALR1.

20 36. A method according to claim 33, 34 or 35 wherein it is determined that at least one test compound binds to GALR2 with a binding affinity between 0 and 100 μ M and with a specificity of greater than 100 fold for GALR2 over GALR1.

37. A method according to any of claims 34-36 wherein it is determined that at least one test compound binds to GALR2 with a specificity of greater than 30 fold for GALR2 over GALR3.

25 38. A method according to any of claims 34-37 wherein it is determined that at least one test compound binds to GALR2 with a specificity of greater than 50 fold for GALR2 over GALR3.

39. A method according to any of claims 34-38 wherein it is determined that at least one test compound binds to GALR2 with a specificity of greater than 100 fold for GALR2 over GALR3.

30

40. A method according to any of claims 34-39 wherein it is determined that the at least one test compound binds to GALR2 with a binding affinity of between 0 and 1 μ M.
41. A method according to any of claims 33-40 wherein the GALR2 comprises at least a portion of human GALR2.
- 5 42. A method according to claim 41 wherein the GALR2 is full-length human GALR2.
43. A method according to any of claims 33-40 wherein the GALR2 comprises at least a portion of non-human GALR2.
44. A method according to claim 43 wherein the GALR2 is rat or mouse GALR2.
45. A method according to claim 43 or 44 wherein the GALR2 is full-length GALR2.
- 10 46. A method according to any of claims 33-40 wherein the GALR2 is a chimeric receptor construct.
47. A method according to any of claims 33-46 wherein a selection of test compounds are screened in a high throughput screening assay.
48. A pharmaceutical composition for use in the prevention or treatment of brain injury, damage or disease, the composition comprising:
 - a) an effective amount of at least one GALR2-specific agonist, or pharmaceutically acceptable salts thereof; and
 - b) a pharmaceutically suitable adjuvant, carrier or vehicle.
- 15 49. A pharmaceutical composition according to claim 48 wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the brain or spinal cord; ischaemic or embolic damage to the brain during cardiopulmonary bypass surgery or renal dialysis; reperfusion brain damage following myocardial infarction; brain disease; immunological damage, chemical damage or radiation damage.
- 20 50. A pharmaceutical composition according to claim 49 wherein the immunological damage is the result of bacterial or viral infection.
51. A pharmaceutical composition according to claim 49 wherein the chemical damage is the result of excess alcohol consumption or administration of chemotherapy agents for cancer treatment.
- 25 52. A pharmaceutical composition according to claim 49 wherein the radiation damage is the result of radiotherapy.

53. A pharmaceutical composition according to claim 48 or 49 wherein the brain disease is one of Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis or variant Creutzfeld Jacob Disease.

54. A pharmaceutical composition according to any of claims 48–53 wherein the GALR2-specific agonist is a polypeptide comprising a portion of the galanin amino acid sequence.

55. A pharmaceutical composition according to claim 54 wherein the GALR2-specific agonist is AR-M1896.

56. A pharmaceutical composition according to any of claims 48–53 wherein the GALR2-specific agonist is a non-peptide small chemical entity.

10 57. A pharmaceutical composition according to any of claims 48–56 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 30 fold binding specificity for GALR2 over GALR1.

15 58. A pharmaceutical composition according to any of claims 48–57 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 50 fold binding specificity for GALR2 over GALR1.

59. A pharmaceutical composition according to any of claims 48–58 wherein the GALR2-specific agonist has a binding affinity for GALR2 of between 0 and 100 μ M and greater than 100 fold binding specificity for GALR2 over GALR1.

60. A pharmaceutical composition according to any of claims 57–59 wherein the GALR2-specific agonist has greater than 30-fold binding specificity for GALR2 over GALR3.

20 61. A pharmaceutical composition according to any of claims 57–60 wherein the GALR2-specific agonist has greater than 50-fold binding specificity for GALR2 over GALR3.

62. A pharmaceutical composition according to any of claims 57–61 wherein the GALR2-specific agonist has greater than 100-fold binding specificity for GALR2 over GALR3.

25 63. A pharmaceutical composition according to any of claims 57–62 wherein the specific-GALR2 agonist has a binding affinity for GALR2 of between 0 and 1 μ M.

64. A pharmaceutical composition according to any of claims 48-63 wherein the pharmaceutically suitable adjuvant, carrier or vehicle is selected from: ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial 5 glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

10 65. A pharmaceutical composition according to any of claims 48-64 which is administered orally or parenterally.

66. A pharmaceutical composition according to claim 65 which is administered orally.

67. A pharmaceutical composition according to claim 66 which is in the form of a capsule or a tablet.

15 68. A pharmaceutical composition according to claim 67 which comprises lactose and/or corn starch.

69. A pharmaceutical composition according to claim 68, further comprising a lubricating agent.

70. A pharmaceutical composition according to claim 69 wherein the lubricating agent is 20 magnesium stearate.

71. A pharmaceutical composition according to claim 66 which is in the form of an aqueous suspension or aqueous solution.

72. A pharmaceutical composition according to claim 71 which comprises an emulsifying agent and/or a suspending agent.

25 73. A pharmaceutical composition according to any of claims 66-72 which comprises sweetening, flavouring and/or colouring agents.

74. A pharmaceutical composition according to claim 65 which is administered by injection, by needle-free device, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

30 75. A pharmaceutical composition according to claim 74 which is administered by injection.

76. A pharmaceutical composition according to claim 75 which is in the form of a sterile injectable preparation.

77. A pharmaceutical composition according to claim 76 wherein the sterile injectible preparation is an aqueous or an oleaginous suspension, or a suspension in a non-toxic parenterally-acceptable diluent or solvent.

78. A pharmaceutical composition according to claim 74 which is administered by needle-free device.

5 79. A pharmaceutical composition according to claim 78 which is a form suitable for administration by needle-free device.

80. A pharmaceutical composition according to claim 79 wherein the form suitable for administration by needle-free device is an aqueous or an oleaginous suspension, or a suspension in a non-toxic parenterally-acceptable diluent or solvent.

10 81. A pharmaceutical composition according to any of claims 77 to 80 wherein the aqueous suspension is prepared in mannitol, water, Ringer's solution or isotonic sodium chloride solution.

82. A pharmaceutical composition according to any of claims 77 to 80 wherein the oleaginous suspension is prepared in a synthetic monoglyceride, a synthetic diglyceride, a fatty acid or a natural pharmaceutically-acceptable oil.

15 83. A pharmaceutical composition according to claim 82 wherein the fatty acid is an oleic acid or an oleic acid glyceride derivative.

84. A pharmaceutical composition according to 82 wherein the natural pharmaceutically-acceptable oil is an olive oil, a castor oil, or a polyoxyethylated olive oil or castor oil.

20 85. A pharmaceutical composition according to claim 82, 83 or 84 wherein the oleaginous suspension contains a long-chain alcohol diluent or dispersant.

86. A pharmaceutical composition according to claim 85 wherein the long-chain alcohol diluent or dispersant is Ph. Helv.

25 87. A pharmaceutical composition according to claim 74 which is administered rectally.

88. A pharmaceutical composition according to claim 87 which is in the form of a suppository for rectal administration.

89. A pharmaceutical composition according to claim 88 wherein the suppository comprises a non-irritating excipient which is solid at room temperature and liquid at rectal temperature.

30 90. A pharmaceutical composition according to claim 89 wherein the non-irritating excipient is one of cocoa butter, beeswax or a polyethylene glycol.

91. A pharmaceutical composition according to claim 74 which is administered topically.

92. A pharmaceutical composition according to claim 91 which is an ointment comprising a carrier selected from mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene-polyoxypropylene compounds, emulsifying wax and water.
93. A pharmaceutical composition according to claim 91 which is a lotion or cream comprising a carrier selected from mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
94. A pharmaceutical composition according to claim 74 which is administered nasally.
95. A pharmaceutical composition according to claim 94 which is administered by nasal aerosol and/or inhalation.
96. A method of inhibiting the death of a cell comprising contacting the cell with an amount of a GALR2-specific agonist effective to inhibit the death of the cell.
97. A method according to claim 96 wherein the cell is a neuron.
98. A method according to claim 96 or 97 wherein the cell is a neuron from the central nervous system.
99. A method according to claim 96, 97 or 98 wherein the cell is a hippocampal or cortical neuron.
100. A method according to any of claims 96 to 99 wherein the cell is a human cell.


Figure 1

Figure 2




Figure 3






Figure 4**A****B**

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/GB2005/000188

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/72 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/03059 A (UNIVERSITY OF BRISTOL; WYNICK, DAVID) 29 January 1998 (1998-01-29) the whole document -----	1-100
Y	MAHONEY SALLY-ANN ET AL: "The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons." JOURNAL OF NEUROSCIENCE, vol. 23, no. 2, 15 January 2003 (2003-01-15), pages 416-421, XP002324293 ISSN: 0270-6474 the whole document ----- -/-	1-100

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents:

- °A° document defining the general state of the art which is not considered to be of particular relevance
- °E° earlier document but published on or after the international filing date
- °L° document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- °O° document referring to an oral disclosure, use, exhibition or other means
- °P° document published prior to the international filing date but later than the priority date claimed

- °T° later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- °X° document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- °Y° document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- °&° document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 April 2005

22/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kalsner, I

INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/GB2005/000188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MAHONEY SALLY-ANN ET AL: "The galanin antagonist M35 has intrinsic agonistic activity in the dorsal root ganglion." NEUROREPORT. 26 AUG 2003, vol. 14, no. 12, 26 August 2003 (2003-08-26), pages 1649-1652, XP009046146 ISSN: 0959-4965 the whole document</p> <p>-----</p> <p>LIU HONG-XIANG ET AL: "Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9960-9964, XP002324295 ISSN: 0027-8424 the whole document</p> <p>-----</p>	
P, X	<p>ELLIOTT-HUNT ET AL.: "Galanin acts as a neuroprotective factor in the hippocampus" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 101, 6 April 2004 (2004-04-06), pages 5105-5110, XP002324298 the whole document</p> <p>-----</p>	1-100

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/000188

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 17-32 (partially) because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 17-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

Inter Application No
PCT/GB2005/000188

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9803059	A 29-01-1998	AT 237346	T	15-05-2003
		AU 3630297	A	10-02-1998
		DE 69721005	D1	22-05-2003
		DE 69721005	T2	09-06-2004
		DK 918455	T3	04-08-2003
		EP 1342410	A2	10-09-2003
		EP 0918455	A1	02-06-1999
		ES 2196349	T3	16-12-2003
		WO 9803059	A1	29-01-1998
		GB 2331301	A ,B	19-05-1999
		JP 2000516212	T	05-12-2000
		PT 918455	T	30-09-2003
		US 2003009777	A1	09-01-2003